Exosome-derived miRNAs as predictive biomarkers for diffuse large B-cell lymphoma chemotherapy resistance
Author(s) -
Yuhua Feng,
Meizuo Zhong,
Shan Zeng,
Leyuan Wang,
Ping Liu,
Xiangyu Xiao,
Yiping Liu
Publication year - 2018
Publication title -
epigenomics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.265
H-Index - 60
eISSN - 1750-1911
pISSN - 1750-192X
DOI - 10.2217/epi-2018-0123
Subject(s) - biology , exosome , diffuse large b cell lymphoma , microrna , microvesicles , lymphoma , chemotherapy , computational biology , cancer research , immunology , genetics , gene
Aim: To analyze the expression profiles, clinicopathological features and chemotherapeutic efficacies of exosome-derived miRNAs in diffuse large B-cell lymphoma (DLBCL). Materials & methods: Next-generation sequencing technique was performed to identify miRNA profiles in exosomes from parental and chemoresistant DLBCL cells. The results were validated by quantitative real-time PCR, and further analyzed by bioinformatics and statistical methods. Results: We identified 37 significantly upregulated and 17 downregulated miRNAs. Of four upregulated miRNAs validated, we found miR-99a-5p and miR-125b-5p were significantly upregulated. Increased levels of exosomal miR-99a-5p and miR-125b-5p in DLBCL patients’ serum were associated with shorter progression-free survival time, and they can predict chemotherapeutic efficacy. Conclusion: Exosomal miR-99a-5p and miR-125b-5p can serve as biomarkers for DLBCL.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom